Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22173799 | 0.94 | FDPS (0.35) | FDPSCYP2D6 | |
| SCHEMBL16500149 | 0.94 | FDPS (0.35) | FDPSCYP2D6 | |
| SCHEMBL31258986 | 0.87 | FDPS (0.38) | FDPSCYP2D6 | |
| SCHEMBL5161559 | 0.87 | FDPS (0.38) | FDPSCYP2D6 | |
| Water SCHEMBL18549355 | 0.84 | FDPS (0.36) | FDPSCYP2D6 | |
| SCHEMBL9947119 | 0.84 | FDPS (0.37) | FDPS | |
| SCHEMBL11051714 | 0.84 | FDPS (0.34) | FDPS | |
| SCHEMBL8432610 | 0.82 | FDPS (0.39) | FDPS | |
| SCHEMBL14812102 | 0.81 | CYP2D6 (0.30) | CYP2D6 | |
| SCHEMBL22572378 | 0.81 | FDPS (0.31) | FDPSCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101443330-A | Heterocyclic non-nucleoside compound, preparation method thereof, pharmaceutical composition and application thereof as antiviral inhibitor | SHANGHAI INST MATERIA MEDICA (CN) | 2009-05-27 | — | — | CN | claimed |
| EP-2030974-A1 | HETEROCYCLIC NON-NUCLEOSIDE COMPOUNDS, THEIR PEPARATION, PHARMACEUTICAL COMPOSITION AND THEIR USE AS ANTIVIRAL AGENTS | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2009-03-04 | — | — | EP | claimed |
| US-20070043093-A1 | Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2007-02-22 | — | — | US | claimed |
| EP-1695968-A1 | THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, THE PREPARATION AND THE USE OF THE SAME | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2006-08-30 | — | — | EP | claimed |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-4553075-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-20240368203-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-11-07 | — | — | US | disclosed |
| WO-2024008122-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 海创药业股份有限公司 | 2024-01-11 | — | — | WO | disclosed |
| CN-117362281-A | PI3K inhibitor and preparation method and application thereof | 海创药业股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2022257960-A1 | BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-115368568-A | Perfluorinated ion exchange resin, preparation method thereof and ion exchange membrane | 国家电投集团氢能科技发展有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-114605401-A | Oxygen-containing five-membered heterocyclic compound, synthesis method, pharmaceutical composition and application | 江南大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005061481-A1 | NOVEL MA CROCYCLES AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004058713-A1 | DIFFERENTIAL TUMOR CYTOTOXOCITY COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-07-15 | — | — | WO | disclosed |
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-07-08 | — | — | US | disclosed |
| EP-0177933-B1 | INTERMEDIATES FOR MAKING 16-PHENOXY AND 16-SUBSTITUTED PHENOXY-PROSTATRIENOIC ACID DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| EP-0177933-A2 | Intermediates for making 16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | MIF, FOXM1, MYADM | FDPS 2504/4885CYP2D6 3064/4885 |
| US-20070043093-A1 | Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same | GLP1R, GCGR, GIPR | FDPS 2850/4885CYP2D6 3788/4885 |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | PIK3CA, PIK3R4, PIK3R1 | FDPS 1026/4885CYP2D6 888/4885 |
| US-20240368203-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | FDPS 4346/4885CYP2D6 4546/4885 |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | FDPS 790/4885CYP2D6 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.